The combination of Ixempra and capecitabine should not be given to patients with moderate or severe liver impairment due to the increased risk of toxicity and death.

The elimination half-life of 8 hours is not increased by liver impairment and old age, but by significant renal disease.

It should also not be used in patients with severe liver impairment.

And, although physical signs of chronic liver dysfunction may not be present, many patients suffer liver impairment leading to liver failure.

Individuals who have liver impairment may require dose reduction of about one half or one third.

The prescribing information recommends that the treatment of the patients with liver impairment "must be approached with caution".

Patients with preexisting bone marrow depression and liver impairment should be treated with caution.

Patients on alpha-blockers or those who have severe kidney or liver impairment should not use Rapaflo.

In liver impairment, the dose of chloramphenicol must therefore be reduced.

There is no standard dose reduction for chloramphenicol in liver impairment, and the dose should be adjusted according to measured plasma concentrations.